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Abstract
Reactive oxygen species (ROS) is the collective term for several oxygen 
containing free radicals, such as hydrogen peroxide. ROS is important in innate 
immunity, protein folding in the endoplasmic reticulum and as a cell signalling 
molecule involved in cellular proliferation, survival, differentiation, and gene 
expression. ROS has been implicated in both hematopoietic stem cell quiescence 
and hematopoietic differentiation. Consequently, ROS is of considerable interest 
as a therapeutic target, with both pro-oxidant and anti-oxidant cellular modulation 
being explored. Recently, it has been established that increased ROS production in 
acute myeloid leukemia (AML) leads to increased glycolysis and metabolic repro-
gramming. It is often stated as a key tenet of the Warburg effect, that transformed 
cells, including AML, show increased aerobic glycolysis accompanied by increased 
cellular glucose uptake and lactate secretion. This review will summarize ROS state 
of the art in acute leukemia and how these reactive molecules re-wire metabolism 
in cancer cells. The review will focus on what are ROS? What are the sources of 
ROS in hematopoietic cells and their function and how this relates to the Warburg 
effect and regulation of metabolic pathways in acute leukemias.
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1. Introduction
To maintain hemostasis, new blood cells must be constantly generated to 
replace those lost through injury, disease, or age. Hematopoiesis, is the process 
where hematopoietic stem cells (HSC) differentiate into mature blood cells and 
is tightly regulated by the bone marrow (BM) micro-environment (or stem cell 
niche; reviewed in [1]), signal transduction pathways (reviewed in [2]), cytokines 
(reviewed in [3]), transcription factors (reviewed in [4]), epigenetics, (reviewed 
in [5]) and metabolic pathways (reviewed in [6]). HSCs are rare, constituting 
only 0.001% of peripheral blood (PB) and 0.05% of BM cells, but are responsible 
for producing a lifetime supply of blood cells. HSCs are cells that able to durably 
self-renew whilst also being multipotent. This differentiation is generally consid-
ered to occur via several intermediate progenitor cells, ultimately terminating in 




The compartmentalization of HSC, their progenitors and terminally differenti-
ated blood cells, into different stages of differentiation, is traditionally based on the 
expression of cell surface proteins (Figure 1). The recent emergence of single cell 
technologies such as fluorescent in situ hybridization, high-throughput single-cell 
quantitative PCR, single cell mass spectrometry and mass cytometry however, have 
led to re-analysis of these models of hematopoietic differentiation [7]. Discrete 
progenitor cell populations, as determined by cell surface markers, have been 
shown to consist of heterogenous populations with different fates [8]. Recently, 
a study by Velten et al., 2017, using a combination of single cell technologies and 
xenotransplantation as functional validation, proposed that early hematopoiesis 
consists of, a cellular continuum of low-primed undifferentiated (CLOUD) hemato-
poietic stem progenitor cells (HSPC), with simultaneous lineage gene expression for 
multiple fates [9]. This study suggested that early discrete stable progenitors do not 
exist, with any lineage determination occurring further downstream than originally 
presumed.
Regardless of provenance, leukemogenesis is characterized by a block in dif-
ferentiation and an accumulation of immature white blood cell blasts with a rapid 
increase in these blasts, characteristic of the acute leukemias. Acute lymphoblastic 
leukemia (ALL) and acute myeloid leukemia (AML) are heterogenous diseases 
with a block in lymphoid or myeloid differentiation, respectively. They occur due 
to one or more genetic insults. Whilst ALL is predominantly a disease of children 
(80%), with a greater than 90% 5 y survival rate [10], in adults long term survival 
stands at only 30–40% [11]. AML in contrast is primarily a disease of the elderly, 
and like adult ALL it’s 5 y survival rate is around 30%, however this falls in the over 
Figure 1. 
Human hematopoiesis. Schematic diagram showing classical model of hematopoietic lineage commitment, with 
phenotypical cell surface markers (red), transcription factors determining differentiation (green box) and 
growth factors involved in myelopoiesis (blue). Hematopoietic stem cell (HSC), cluster of differentiation (CD), 
hematopoietic progenitor cell (HPC), common myeloid progenitor (CMP), common lymphoid progenitor 
(CLP), interleukin (IL), granulocyte macrophage (GM) colony-stimulating-factor (CSF), stem cell factor 
(SCF), thrombopoietin (TPO), erythropoietin (EPO), granulocyte myeloid progenitor (GMP), runt-related 
transcription factor 1 (RUNX1), transcription factor stem cell leukemia (SCL), ccaat enhancer binding 
proteins (C/EBP), friend of GATA protein 1 (FOG-1).
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60’s to a particularly bleak 10% [12]. In ALL, recent advances for example in the 
use of tyrosine kinase inhibitors and CAR-T cell therapy, have started to suggest 
improvements to overall survival [10]. However, in patients fit enough to tolerate 
chemotherapy, the standard treatment for AML since 1973 has been a seven-day 
continuous intravenous infusion of cytarabine (Ara-C) (100–200 mg/m2) and 3 
daily doses of daunorubicin (45–90 mg/m2), sometimes followed by allogeneic or 
autologous stem cell transplantation, and despite some recent advances (reviewed 
in [13, 14]), current treatments appear to have reached their efficacious limits and 
new therapies are required.
One potential therapeutic opportunity involves exploiting the metabolic differ-
ences that exist between malignant and non-malignant cells [15]. Differences that, 
in AML at least, appear exacerbated by cellular levels of reactive oxygen species 
(ROS) [16].
2. Reactive oxygen species
ROS is the collective term for several oxygen containing free radicals and other 
reactive molecules, such as hydrogen peroxide (H2O2). Physiologically, ROS are 
initially generated via the univalent reduction of molecular oxygen which gener-
ates superoxide (O2•−). Superoxide (t1/2 = 1 μs) subsequently dismutates to H2O2 
(t1/2 = 1 ms) [17], either spontaneously or via the catalytic action of the enzyme 
superoxide dismutase (SOD), or reacts with other ROS molecules, forming a variety 
of other ROS (Figure 2). Functionally, ROS is important in innate immunity, 
Figure 2. 
Formation of reactive oxygen species (ROS). Diatomic oxygen (O2) is univalently reduced by peroxisomes 
(PO), xanthine oxidase (XO), the electron transport chain (ETC), or NADPH oxidase (NOX) to generate 
superoxide (O2
•−). PO may also reduce O2 directly to form H2O2. O2
•− may then dismutate to H2O2 either 
spontaneously or through the enzymatic action of superoxide dismutase (SOD). Hydroxyl radicals (OH•) 
may then be formed from H2O2 via the formation of hypochlorous radical (HOCl) in the PO, or via Fenton 





protein folding in the endoplasmic reticulum and as a cell signalling molecule 
involved in cellular proliferation, survival, differentiation and gene expression [18].
There are several sources of cellular ROS, including the mitochondria, the 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase family of enzymes 
(NOX), the cytochrome P450 enzymes, peroxisomes and the metabolic enzyme 
xanthine oxidase (XO).
2.1 Sources of ROS: electron transport chain
Generation of ROS by the mitochondria is primarily a function of ‘electron 
leakage’ from the electron transport chain (ETC), however, mitochondrial ROS 
may also be generated as a result of numerous enzymes including monoamine 
oxidase, cytochrome b5 reductase, glycerol-3-phosphate dehydrogenase, aconi-
tase, pyruvate dehydrogenase and α-ketoglutarate dehydrogenase (reviewed in 
[19]). Mitochondrial ROS production resulting from the ETC generates O2
•−, and 
is thought to occur as result of one of three mechanisms. The first mechanism is 
a consequence of a high NADH/NAD+ ratio, and results from oxygen interacting 
with fully reduced FMN. Mitochondrial ROS generated by this mechanism has been 
observed due to mitochondrial mutation, physiological damage such as ischemia 
or aging, and only small amounts of ROS are thought to be generated via these 
mechanisms in normally respiring cells [20]. The second mechanism occurs when 
there is a high level of reduced co-enzyme Q (CoQH2) in complex II, which in the 
presence of a high proton motive force generated by the proton pump, force elec-
trons back into complex I in a process known as reverse electron transport (RET). 
Whilst RET generated ROS has also been implicated in diseases such as ischemia, it 
is now also thought to be involved as a cell signalling molecule in metabolic adapta-
tion, myeloid differentiation and response to bacterial infection [21]. The third 
mechanism of ROS generation by the ETC occurs at complex III and has also been 
implicated in ROS signalling. The formation of O2
•− occurs at the ubiquinol oxida-
tion centre (Qo) site of the cytochrome bc1 complex, in which fully oxidized CoQ 
supports formation of O2
•−, through the transfer of electrons from reduced heme b1 
to molecular oxygen [22]. Generation of O2
•− by complex I and II occurs exclusively 
in the mitochondrial matrix, whereas O2
•− generated by complex III also occurs in 
the intermembrane space. O2
•− generated in the mitochondrial matrix is rapidly 
converted to H2O2 by mitochondrial SOD (Mn-SOD), whereas O2
•− generated in the 
intermembrane space travels through the outer mitochondrial membrane prior to 
conversion to H2O2 by cytosolic SOD (Cu/Zn-SOD).
2.2  Sources of ROS: nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase family of enzymes (NOX)
Whilst mitochondrial oxidative phosphorylation is a major source of intracel-
lular ROS, the main source of extracellular ROS involves the nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase family of enzymes (NOX). The NOX 
family of enzymes comprise of seven members, NOX1–5 and dual oxidase (DUOX) 
1 and 2. NOX enzymes are transmembrane proteins that transfer electrons from 
NADPH to molecular oxygen, generating O2
•− (or H2O2), which can then be con-
verted to other forms of ROS. Different NOX isoforms share conserved structural 
features comprising of six helical transmembrane domains (TM) (with helix III 
and helix V containing two heme-binding histidines), and a C-terminus cytosolic 
domain (DH), which allows binding of FAD and NADPH (Figure 3). Difficulties 
in obtaining suitable levels of NOX proteins mean that to date relatively little 
crystal structure data is available. However, a recently published report [23], has 
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elucidated the structure of the TM and DH domains (common to all NOX isoforms) 
of Cylindrospermum stagnale NOX5 in complex with FAD. In this structure, the six 
transmembrane helices of TM domain form a pyramidal shape with the base on 
the cytosolic side, a N-terminus α-helix runs parallel to the cytosolic side of the 
membrane and the heme groups sit in cavities formed by helices II–V, so that one is 
positioned near the cytosolic side of the membrane (heme 1) and the other on the 
outer side (heme 2). The DH domain, located on the cytosolic side, contains two 
pockets, one for FAD binding and one for NADPH binding. The FAD is positioned 
so that the flavin is in direct contact with heme 1 of the TM, to promote interdomain 
electron transfer. The proposed mechanism of electron transfer then involves 
NADPH donating its electron to FAD, which in turn donates an electron to heme 
1 and then to heme 2 via Trp378 (equating to Phe 215 in human NOX2, Phe 200 in 
human NOX4 and Val 362 in human NOX5) of the loop between helix II and III of 
the TM, before reduction of molecular oxygen, via a final electron transfer step 
generates O2
•− (Figure 3).
From a metabolic perspective, one source of NOX2 activation results when cells 
experience intermittent hypoxia. Under this condition activation of the metabolic 
enzyme XO, an enzyme important in the catabolism of purines and a major source 
of cellular ROS, occurs [24]. XO activation leads to increased ROS, which induces 
Ca2+ activation of protein kinase C, an enzyme important in cell signalling, migra-
tion of p47phox and p67phox to the cell membrane, resulting in activation of the NOX2 
complex (Figure 3). Finally it is important to note, from a cell signalling perspec-
tive, that extracellular H2O2 (which is rapidly formed from O2
•−) is readily trans-
ported across the cell membrane via the transmembrane water permeable channel 
protein family of aquaporins [25, 26].
3. Role of ROS on normal hematopoiesis
ROS has been implicated in both HSC quiescence and hematopoietic differentia-
tion. HSC reside in the bone marrow and their quiescence is known to be negatively 
regulated by ROS. Forkhead box O (FOXO) transcription factors are involved in 
Figure 3. 
Generation of superoxide (O2
•−) by NADPH Oxidase (NOX). Schematic diagram showing the major 
structural features of NOX2, it’s activation by phosphorylation (P) of p67phoxand p47phox and the assembly 
of the major subunits of the NOX complex, and the generation of superoxide via electron transfer from 
NADPH to flavin adenine dinucleotide (FAD) to heme groups to diatomic oxygen. Guanosine triphosphate 




cell-cycle arrest and apoptosis and are activated in response to oxidative stress 
whereupon they translocate to the nucleus [27]. Translocation of FOXO4 to the 
nucleus has been shown to be a function of redox signalling, where oxidation of cys-
239 by ROS mediates the formation of disulphide bonds with nuclear import recep-
tor transportin-1, which in turn allows nuclear localization [28]. FOXO deactivation 
occurs as a result of phosphorylation in response to activation of the regulatory cell 
cycle PI3K/AKT/mTOR pathway, resulting in their export from the nucleus and 
subsequent degradation in the cytoplasm [29]. Studies in murine HSC have shown 
that deletion of FOXO3a, which upregulates transcription of Mn-SOD [30], results 
in decreased HSC renewal [31] which is mediated by the tumor suppressor protein 
ataxia-telangiectasia mutated (ATM) and is accompanied by elevated ROS levels 
and myeloid lineage expansion [32]. Deletion of ATM in mice resulted in BM failure 
which was restored following treatment with antioxidants [33]. In a different study, 
isolation of murine HSC into ROS high and ROS low populations showed that the 
ROS low population maintained self-renewal capacity following serial transplanta-
tions, whilst the self-renewal capacity of the ROS high population was exhausted 
following the third serial transplantation. Treatment of the ROS high HSC with 
the antioxidant N-acetyl cysteine (NAC), the p38 inhibitor SB203508 or rapamycin 
(a mTOR inhibitor), restored self-renewal activity [34]. Interestingly, the ROS 
high population in this study also exhibited a decreased ability to adhere to cells 
containing calcium sensing receptors, whilst NOX generated ROS has additionally 
been implicated in osteoclast differentiation in human mesenchymal cells, further 
emphasizing a potential regulatory role of ROS, in the BM niche [35].
Whilst these increased ROS levels are associated with HSC losing quiescence, 
it has also been shown, in the human megakaryocytic cell line MO7e, that hema-
topoietic cytokines, such as granulocyte macrophage-colony stimulating factor, 
interleukin-3, stem cell factor and thrombopoietin all increase ROS levels [36]. In 
megakaryopoiesis, ROS has been shown to increase platelet production and matura-
tion in the chronic myeloid leukemia (CML) cell line MEG-01 and primary human 
megakaryocytes [37], which in murine models is mediated by the transcription 
factor NF-E2 [38]. Following lineage commitment, megakaryocyte progenitors 
undergo endomitosis (chromosomal replication in the absence of cell division), 
which in murine cells is potentially mediated by NOX1-derived ROS [39]. In human 
HSC, NOX-derived ROS has also been shown to be crucial for megakaryocyte dif-
ferentiation via activation of ERK, AKT and JAK2 signalling pathways [40], whilst 
another study revealed the importance of cytochrome P450 2E1-generated ROS in 
megakaryocyte differentiation in human HSC [41]. As noted above, increased ROS 
in HSC has been associated with expanded myelopoiesis. Interestingly, a recent 
study using murine CMP, showed that higher levels of ROS impeded megakaryo-
poiesis, instead directing differentiation of CMP into GMP [42]. Finally, ROS has 
also been shown to induce differentiation of the promonocytic cell line, U937, 
into macrophages [43], and the differentiation of primary human monocytes into 
dendritic cells [44].
4. Role of ROS on solid tumors and leukemia development
One of the first studies implicating ROS in carcinogenesis was performed in 
mice subcutaneously injected with C3H mouse fibroblasts, that had been previously 
cultured in vitro with neutrophils stimulated with 12-O-tetradecanoylphorbol-13-
acetate (TPA) stimulated or unstimulated or with the ROS generating enzyme XO 
and hypoxanthine. In this study approximately 20% of mice treated with these cells 
developed tumors within 13–22 weeks compared to none of the control mice [45].  
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In 1991, analysis of H2O2 production in human melanoma, colon, pancreatic, neu-
roblastoma, breast and ovarian cancer cell lines, revealed constitutively active H2O2 
production over a 4 h period, generating H2O2 levels similar to those observed in 
TPA stimulated neutrophils, suggesting increased ROS production may be a feature 
of transformation [46]. Later, studies in patients with liver disease suggested ROS 
plays a part in hepatocarcinogenesis [47], and levels of Cu/Zn-SOD are significantly 
lower in hepatoma tissue than normal human liver tissue [48]. Further, homozygous 
deletion of Cu/Zn-SOD in mice results in decreased lifespan, with 70% developing 
hepatocarcinoma or benign nodular hyperplasia [49], whilst homozygous deletion 
of Mn-SOD in mice is lethal within two weeks of birth [50]. In the same study, het-
erozygous deletion of Mn-SOD resulted in increased incidence of hemangioma and 
adenocarcinoma and significant increases in the incidence of lymphoma. Currently, 
elevated ROS levels have been reported in many solid tumors and the role they play 
in tumorigenesis is complex and multifaceted (reviewed in [51]).
In leukemia, a study which collected blood samples from ALL and CML patients 
samples and compared them with normal blood samples showed elevated levels of 
ROS in both ALL and CML patients [52], whilst elevated levels of NOX generated 
ROS, are observed, alongside increased proliferation in both AML models and AML 
patient samples when compared with healthy controls [53]. Reactions of ROS with 
DNA can generate numerous oxidised bases, including 8-hydroxy-2-deoxyguano-
sine (8-OHdG) which causes G:C to T:A DNA transversions (reviewed in [54]). 
Increased levels of 8-OHdG have been observed in patients with breast cancer [55], 
gastric carcinomas [56], lung cancer [57] and colorectal cancer [58]. In leukemia, 
a study of 116 Chinese children with either ALL or AML revealed significantly 
elevated levels of 8-OHdG, whilst 8-OHdG levels were also significantly elevated in 
relapsed AML adult patients [59].
As a signalling molecule, ROS can lead to hyperactivation of the PI3K pathway, 
a common feature of many cancers, resulting in increased cell survival, VEGF 
production, secretion of MMP (reviewed in [60]) and inactivation of FOXO [32]. 
In AML, constitutive activation of the PI3K/AKT pathway is frequently observed 
[61, 62], however the role of FOXO is less clear. A recent study revealed that FOXO1 
expression in osteoblasts mediated β-catenin initiated AML [63], whilst a study of 
AML patient samples showed that 40% exhibited FOXO activation, that upon inhi-
bition resulted in myeloid differentiation and AML cell death [64]. Additionally, 
in both CML and AML the BCR-ABL fusion protein and FMS-like tyrosine kinase 
receptor 3 internal tandem duplications (FLT3-ITD) have been shown to lead to 
phosphorylation of AKT resulting in increased activation of NOX, and increased 
ROS production (reviewed in [65]), which may in turn reinforce PI3K/AKT 
activation.
5. Metabolism and cancer
Broadly defined, cellular metabolism involves a series of catabolic or anabolic 
chemical reactions which generate or use energy as part of this process. In che-
motrophs this energy is obtained through the oxidation of nutrients, with the 
energy typically stored in the form of ATP. Whilst in higher organisms a plethora of 
enzymatically catalyzed metabolic reactions occur, which are all part of different 
interconnecting metabolic pathways with multitudinous feedback mechanisms. 
These pathways are evolutionarily highly conserved with the citric acid cycle, for 
example, essentially a feature in all terrestrial life. There are three main classes 
of molecules involved in metabolism; carbohydrates, proteins and lipids that are 
either catabolized to generate energy or energy stores or used by anabolic pathways 
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in the synthesis of, for example, nucleotides and structural molecules such as cell 
membranes. In mammals, a triumvirate of glycolysis, citric acid cycle and the ETC 
are central to the generation of ATP, with glycolysis and the citric acid cycle con-
tributing 2 ATP molecules each and the ETC generating up to 34 ATP molecules in a 
process collectively termed aerobic respiration (reviewed in [66]).
Given the skew towards ATP production in the ETC, Otto Warburg’s observa-
tion in 1956 that aerobic glycolysis was a hallmark feature of cancer cells [15], 
was initially attributed to being the result of defective mitochondria in malignant 
cells, and initially raised little interest. However, this hypothesis is now known in 
most cases to be incorrect (reviewed in [67]) and instead, it has been shown that 
mitochondrial respiration is often necessary in tumorigenesis [68]. However, given 
its ubiquity and despite its inefficiency when compared with ETC, it is clear that 
the phenomenon of increased aerobic glycolysis (eponymously titled ‘The Warburg 
Effect’), must offer cancer cells some competitive advantage, although its exact 
ontology remains unclear. One hypothesis contends that whilst inefficient, aerobic 
glycolysis generates ATP at a rate 10–100 times faster than oxidative phosphoryla-
tion, therefore supplying cancer cells with energy at a faster rate. This increased 
glycolytic flux could then, potentially generate more nucleotides, amino acids and 
lipids for biosynthesis as well as generating the reducing agent NADPH, to deal 
with the increased levels of ROS common in many cancer cells [69]. Alternatively, 
increases in excreted lactate as a result of aerobic glycolysis would likely generate a 
more acidic microenvironment, breaking down stromal membrane structures and 
potentially increasing cancer cell motility and metastasis [70].
5.1 NADPH: a link between ROS and metabolism in cancer
It has been shown that activation of the tumor suppressor protein ATM by ROS 
promotes glucose-6-phosphate dehydrogenase (G-6-PD) activity, the first step of 
the pentose phosphate pathway (PPP), which in turn generates NADPH [71]. Given 
that major cellular antioxidant systems, ultimately rely on NADPH to provide their 
reducing power, it is perhaps not surprising that ROS in both normal and aberrant 
cellular processes is inextricably linked with metabolism. In the cytosol, NADPH 
is primarily generated through the PPP, whilst a number of mechanisms exist for 
mitochondrial NADPH generation [72], which include the serine synthesis path-
way (SSP) (via the folate cycle) [73] and the action of the citric acid cycle enzyme 
isocitrate dehydrogenase (IDH). IDH1 and IDH2 are commonly mutated in AML 
[74], although in this context NADPH is consumed, and the D-2-hydroxyglutarate 
generated leads to stabilization of the hypoxia regulator, hypoxia inducible factor 
alpha (HIF-1α) [75].
HIF-1α as a target of ROS is controversial [76], however it is overexpressed 
in many cancers where it induces expression of numerous glycolytic genes. The 
ROS regulated transcription factor nuclear-related factor 2 (NRF2) has also been 
shown to modulate metabolism in lung cancer cell lines, through the upregulation 
of enzymes involved in the NADPH production, notably G-6-PD, IDH1 and malic 
enzyme 1 [77] and high NRF2 levels have previously been reported in AML [78]. 
Furthermore, the tumor suppressor protein TP53 is also important in regulating 
metabolism. Homozygous deletion of TP53 in mice results in decreased oxygen 
consumption arising from decreased mitochondrial respiration [79]. TP53 expres-
sion has been shown to inhibit, both glucose transporter (GLUT) 1 and 4 and the 
glycolytic enzyme phosphoglycerate mutase (PGAM) (reviewed in [80]) leading 
to decreased glycolysis and potentially increased metabolism via the PPP and SSP. 
Finally, TP53 also upregulates the apoptosis regulator (TIGAR) an enzyme which has 
an active domain similar to 6-Phosphofructo-2-kinase/fructoste-2,6-bisphosphatase 
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(PFKFB). TIGAR catalyzes the reaction of fructose-2,6-bisphosphate (F-2,6-BP) to 
fructose-6-phosphate (F-6-P), which inhibits glycolysis, redirects metabolites into 
the PPP, generating NADPH [81].
5.2 ROS regulation of metabolic pathways
Changes of cellular ROS levels in both normal signalling as well cell signalling 
following cellular transformation result in changes in numerous signalling pathways 
controlling multiple cellular functions including growth, proliferation and differ-
entiation. A number of these signalling pathways, exercise regulatory control over 
various metabolic pathways, which in turn modulate ROS levels via several feedback 
mechanisms (Figure 4). In leukemia, mutations in the RAS gene are present in 
about 15% of hematological malignancies [82]. RAS activates the PI3K/AKT/mTOR 
pathway which promotes nucleotide biosynthesis and lipid synthesis (reviewed in 
[83]) as well as HIF-1α, which upregulate glycolysis via the activation of numerous 
glycolytic genes. In addition to HIF-1α, other ROS activated transcription factors 
are important in metabolic regulation such as STAT3, which has been shown to pro-
mote glycolysis in hepatocellular carcinoma cell lines [84], FOXO3A, which inhibits 
glycolysis via activation of tuberous sclerosis 1 protein [85] and NF-κB which was 
shown to upregulate GLUT3 in mouse embryonic fibroblasts [86].
Nuclear localization of the glycolytic enzyme pyruvate kinase muscle 2 
(PKM2) is also ROS mediated, where it acts as a co-factor in the activation of the 
transcription factor, c-MYC. RAS also activates c-MYC which is overexpressed 
in greater than 50% of human cancers and c-MYC has been shown to activate 
glycolysis via the upregulation of GLUT, the glycolytic enzymes hexokinase (HK), 
Figure 4. 
Regulation of metabolic pathways. Schematic illustration outlining some of the regulatory mechanism involved 
in glycolysis and other key metabolic pathways. Transcription factors are in pink and signalling pathways 
in blue. Reactive oxygen species (ROS), forkhead box O (FOXO), pyruvate kinase muscle 2 (PKM2), signal 
transducer and activator of transcription (STAT), nuclear factor kappa-light-chain-enhancer of activated 
B-cells (NF-κB), glucose transporter (GLUT) hypoxia inducible factor-1 alpha (HIF-1α), tumour suppressor 
protein 53 (TP53), glycogen synthase kinase 3β (GSK-3β), isocitrate dehydrogenase (IDH), succinate 
dehydrogenase (SDH), fumarate hydratase (FH), protein kinase B (AKT), mammalian target of rapamycin 




phosphoglucose isomerase (PGI), phosphofructokinase (PFK), glyceraldehyde-
3-phosphate dehydrogenase (GAPDH), phosphoglycerate kinase (PGK), PKM2, 
as well as lactate dehydrogenase A (LDHA), pyruvate dehydrogenase kinase 1 
(PDK1) and PFKFB3 (reviewed in [87]). Increased glutaminolysis is also a target 
of c-MYC, which upregulates the glutamine transporter ASCT2 and a key enzyme 
glutaminase. Additionally, c-MYC was shown to upregulate both phosphoglycerate 
dehydrogenase (PHGDH) which catalyzes the first step of the SSP, serine hydroxy-
methyltransferase, part of the folate cycle as well as several genes involved in fatty 
acid metabolism and the citric acid cycle (reviewed in [67]). In contrast TP53 is 
known to inhibit glycolysis through inhibition of GLUT1, GLUT4 and PGAM and 
through activation of TIGAR and synthesis of cytochrome c oxidase 2 (SCO2). 
Inhibition of glycolysis also occurs due to the regulatory role of miRNA. For 
example, miR-195-5p inhibits GLUT3, miR-143 inhibits HK2 and miR-155 inhibits 
HIF-1α. Furthermore, TP53 induces miR-34a which suppresses HK1, HK2, GPI and 
PDK1, as well as sirtuin 1, which activates FOXO1, NF-κB and in a positive feedback 
loop TP53 (reviewed in [80]).
5.3 Metabolism and leukemia
Given the role that ROS plays in regulating metabolism, it is not surprising that 
expression of nearly all enzymes associated with glycolysis have been shown to be 
altered in solid tumors, a pattern also observed in leukemia. In ALL, micro-array 
analysis showed significant upregulation of PFK as well as the glucose transporters 
GLUT1 and GLUT4 in pediatric B-ALL samples [88], whilst deletion of GLUT1 
in primary human B-ALL cells suppressed leukemic progression in vivo [89]. In 
AML, upregulation of GLUT1 mRNA [90] and the fructose transporter GLUT5 
[91] have also been reported to be associated with poor outcome in AML patients. 
Furthermore, NOX generated ROS has previously been reported to modulate cel-
lular glucose uptake through increased GLUT1 activity, in leukemic cell lines [92]. 
In Philadelphia+ ALL (Ph+ALL) GLUT5 has been found to be upregulated at both 
the mRNA and protein level [93]. Song et al have identified HK2 overexpression as 
a feature of AML patients who failed to show remission [90], whilst decreased pro-
liferation in the AML cell line, KG-1, was observed upon knock-down of PGI with 
shRNA [94]. The HK inhibitors 2-deoxy-D-glucose and 3-bromopyruvate have both 
been shown to be cytotoxic in AML patient samples harboring a FLT3-ITD mutation 
both alone and in combination with sorafenib [90, 95]. In chronic lymphocytic leu-
kemia (CLL), a study by Ryland et al., 2013 showed increased expression of glycer-
aldehyde phosphate dehydrogenase (GAPDH) in CLL patients compared to healthy 
controls [96]. Proteomic studies revealed elevated levels of aldolase A (ALDO(A)), 
ALDO(C) and enolase 1 (ENO1) in the chemoresistant leukemia cell line K562/
A02 when compared with parental K562 cells and in the case of ENO1 this was 
confirmed by western blot [97]. Elevated levels of ENO2 have also been reported 
in patients with ALL where it is associated with lower overall survival [98], whilst 
PGAM is upregulated in both AML and CML patient samples [99]. LDH is a tetra-
mer which exists as five isoforms, comprising of two subunits LDHA and LDHB 
in different combinations and encoded by the LDHA and LDHB genes [100], with 
LDHA strongly catalyzing pyruvate to lactate and LDHB preferentially catalyzing 
the reverse reaction. In B-ALL, mRNA expression levels of LDHB were shown to 
be decreased [88], suggesting increased lactate production, whilst more recently 
increased serum levels of LDH were found in patients with B-ALL in conjunction 
with increased levels of total oxidant status and decreased total anti-oxidant status 
[101]. Another recent study involving 204 patients with acute leukemia’s also 
reported that LDH plasma levels were significantly elevated compared to healthy 
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controls and were also increased in relapse patients compared to those in complete 
remission [102]. Recently, it was shown that ROS dependent proliferative increases 
observed in hematopoietic models [103] were also accompanied by increased 
glucose uptake and expression of the regulatory glycolytic enzyme PFKFB3 [53], 
whilst downregulation of this enzyme suppressed growth both in vivo and in vitro 
[16]. This study also reported that metabolomic analysis comparing AML patient 
samples with high/low levels of ROS, which showed significantly elevated levels 
of glucose, glucose-6-phosphate (G-6-P) and F-6-P in the ROS high patients. 
Another metabolomic study involving serum from 400 AML patients compared 
with 446 healthy controls, identified elevated levels of the glycolytic intermediates 
3-phosphoglycerate (3-PG), pyruvate and lactate as conferring a poor prognosis 
for survival [104]. Interestingly, a recent study showed that the bromodomain and 
extra-terminal protein inhibitor JQ1, which has shown promise in ALL by targeting 
c-myc, downregulates expression of HK2, PKM2 and LDHA both at the transcrip-
tional and protein level [105].
The citric acid cycle is a series of metabolic reactions involving oxidation/reduc-
tion reactions, which generate nicotinamide adenine dinucleotide (NAD)H and 
flavin adenine dinucleotide (FAD)H via the transfer of hydride ions, thus providing 
electrons for the ETC which is a major source of cellular ROS (reviewed in [106]). 
Mutations of IDH, which catalyzes the decarboxylation of isocitrate to alpha-
ketoglutarate are frequently reported in AML (reviewed in [107]). Characterization 
of the inhibitor AG-221, which has been shown to inhibit mutant IDH2 in AML 
cells in vitro and in vivo and is currently undergoing phase I/II clinical trials [108], 
as is the IDH1 inhibitor, AG-120 [109]. A metabolomic study which examined a 
cohort of 183 patients with de novo AML matched with 232 healthy controls showed 
significant differences in citrate levels between AML patients and controls [110]. 
In pediatric ALL a recent metabolomic study revealed increased metabolites of 
glycolysis, the citric acid cycle and the PPP in patients testing positive for measur-
able residual disease compared to those testing negative [111]. Interestingly use of 
nicotinamide phosphoribosyltransferase (NAMPT) inhibitors on ALL cell lines 
and patient samples showed cytotoxicity in vitro. NAMPT is a key enzyme in the 
synthesis of the oxidizing agent NAD+, in both glycolysis and the citric acid cycle.
The SSP branches from the glycolytic pathway at the glycolytic intermedi-
ate 3-PG, where it is converted into 3-phosphohydroxypyruvate by the enzyme 
PHGDH, followed by conversion to phosphoserine by phosphoserine amino-
transferase 1 and finally to serine by the action of the enzyme phosphoserine 
phosphatase (reviewed in [73]). Regulation of the SSP is achieved through 
2-phosphoglycerate (2-PG) which activates PHGDH whilst serine activates the 
tetrameric form of PKM2 leading to increased glycolysis and decreased levels of 
2-PG. Importantly serine can enter the folate cycle, which provides another route 
for the generation of NADPH, which has been shown to contribute to tumor growth 
in vivo [112]. Whilst overexpression of PHGDH has been reported in melanomas, 
colorectal and breast cancers, little has been published from a leukemia perspective. 
Knock-down of PHGDH has been shown to inhibit the growth of the leukemia cell 
line, HL-60 [113], and in multiple myeloma increased expression of PHGDH led to 
increased SSP activity and antioxidant capacity in cells resistant to treatment with 
the proteasome inhibitor bortezomib [114].
The PPP generate nucleotides for biosynthesis and is a major source of cellular 
NADPH, an important cellular antioxidant. The first step involves the dehydrogena-
tion of G-6-P to 6-phosphogluconolactone (6-PG) catalyzed by G-6-PD and the 
conversion of NADP+ to [115]. Gluconolactonase catalyzes the hydrolysis of 6-PG 
to 6-phosphogluconate, which is then catalyzed by 6-phosphogluconate dehydro-
genase (6-PGD) to ribulose-5-phosphate (Ru-5-P) alongside the generation of a 
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second NADPH. Ru-5-P can then be converted into ribose-5-phosphate (R-5-P) by 
the enzymatic action of ribulose-5-phosphate isomerase. R-5-P can then be used 
in the synthesis of nucleotides. Alternatively, where redox homeostasis and not 
nucleotide synthesis is the major requirement of the cell Ru-5-P can be catalyzed 
by ribulose-5-phosphate epimerase, into xyulose-5-phosphate (X-5-P) and via a 
series of further metabolic reactions back into the glycolytic intermediates F-6-P 
and glyceraldehyde-3-phosphate. G-6-PD is the rate limiting step of the PPP and 
is regulated by the NADP+/NADPH ratio, RAS/PI3K signalling and phosphoryla-
tion by Src, whilst 6-PGD is inhibited by 3-PG [99]. In cancer, aberrant RAS 
signalling or activation of Src can promote activation of the PPP. In AML, a recent 
study showed upregulation of G-6-PD mRNA in approximately 60% of patients, 
although it was not correlated with overall survival or relapse [116]. Targeting of 
xenograft mice injected with the leukemic cell line K562, with the antimalarial drug 
dihydroartemisinin and the 6-PGD inhibitor Physicon resulted in decreased tumor 
growth, whilst primary leukemia cells isolated from the PB of AML patients showed 
significantly decreased viability, with no toxicity observed in hematopoietic cells 
isolated from healthy individuals [117]. A metabolomic study comparing primary 
AML samples with either high or low levels of ROS, have also shown increased 
levels of the PPP metabolites sedoheptulose-7-phosphate and Ru-5-P in the samples 
with higher ROS levels [16]. Another study, using both AML cell lines and patient 
material, showed increased glucose metabolism and increased flux through the 
PPP, alongside increased G-6-PD mRNA expression [118]. Importantly, this study 
showed that use of the G-6-PD inhibitor 6-aminonictoinamide (6-AN) in AML 
cell lines induced both in vitro and in vivo cytotoxicity, and induced apoptosis in 
primary AML cells but not normal HPCs. In B-ALL, redirection of carbon from 
the glycolytic pathway to the PPP by the serine/threonine-protein phosphatase 2A 
(PP2A), has been shown to occur to combat cellular oxidative stress. Synergistic 
inhibition of G-6-PD by 6-AN and PP2A inhibitor LB100 induced cell death in 
patient derived Ph+ALL [119].
Lipid metabolism has also been shown to be dysregulated in both solid tumors 
and hematological malignancies (reviewed in [120]). Increased fatty acid oxidation 
(FAO) allows cancer cells to overcome metabolic and oxidative stress through the 
generation of ATP and NADPH. Significant changes to lipid metabolite levels are 
seen in AML patient samples with either high levels or low levels of ROS [16], whilst 
suppression of NOX2 has also been shown to increase FAO [121]. Furthermore, 
inhibition of the FAO using Avocatin B results in decreased NADPH levels and ROS 
dependent cell death in primary human AML samples but not normal mononuclear 
cells [122]. In ALL, use of L-asparaginase has been shown to increase FAO activity 
as a metabolic escape mechanism, however use of the FAO inhibitor etomoxir in 
combination with L-asparaginase has been shown to increase sensitivity of both 
leukemic cell lines and patient samples [123].
6. Conclusions
In the last twenty years, it has become increasingly clear that ROS play a signifi-
cant role in cellular signalling, particularly pathways associated with growth, differ-
entiation and survival, whilst its roles in HSC quiescence and normal hematopoiesis 
have started to be delineated. In many cancers including hematological malignan-
cies, ROS levels have been shown to be elevated, leading to aberrant signalling 
in these pathways. Previously, arguments for both the use of anti-oxidant and 
pro-oxidant treatments in leukemia have been made (reviewed in [124]). Despite 
the transformation of survival rates in patients with acute promyelocytic leukemia 
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using arsenic trioxide [125] cancer cells often upregulate the production of antioxi-
dants, and downregulate pro-apoptotic pathways such as TP53, as a response to high 
ROS, allowing them to escape apoptosis. In addition, it has been shown that both 
cancer stem cells [126, 127] and leukemic stem cells [128] exhibit low ROS levels, 
suggesting that even if treatment with pro-oxidants eliminates the bulk of cancer 
cells, cancer/leukemic stem cells may survive and relapse occur. Conversely, studies 
involving the use of antioxidants in treatment and epidemiological studies of 
antioxidant use, have shown mixed results (reviewed in [129, 130]). Increasingly it 
is becoming apparent that increased levels of ROS are leading to changes in signal-
ling pathways directly or indirectly controlling metabolism, as a mechanism for 
managing oxidative stress. Whilst, it has long been known that cancer cells exhibit 
greatly altered metabolism, only recently have the purposes behind this altered 
metabolism, started to be elucidated. Consequently, synergistic treatments involv-
ing the use of metabolic inhibitors, alongside classical treatments for leukemias are 
being explored. Future work, elucidating the intricate mechanisms governing the 
interplay between ROS and metabolism, alongside new and more specific metabolic 
inhibitors provide much promise for the future treatment of leukemia.
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